2015 -2017 Senior Director, In Vivo and Exploratory Immunology @
2013 -2015 Senior Director @
2008 -2011 Director, Disease Biology @
2008 -2012 Director, Translational Research @
2008 -2012 Co-Founder and Scientific Advisor @ Advanced Immune Therapeutics
2004 -2008 Senior Director Research @
2000 -2004 Director, Research and Clinical Immunology @ AltaRex Corp.
1998 -2000 Director, Preclinical Research @ AltaRex Corp.
1996 -1997 Scientist @ AltaRex Corp.
Birgit Schultes Education
Boston University
Advanced Management Development
2009-2011
MBC
(Project Management)
2010-2010
The University of Bonn
Ph.D. (Immunology)
1989-1994
The University of Bonn
Masters (Biology)
Birgit Schultes Skills
Immunology
Oncology
Antibodies
Clinical Development
In Vitro
In Vivo
Cell
Translational Research
Animal Models
Flow Cytometry
Molecular Biology
Biotechnology
ELISA
Cell Biology
Drug Discovery
Cell Based Assays
Immunohistochemistry
Western Blotting
Pharmacology
Cancer
Cell Culture
qPCR
Immunoassays
GLP
Biomarkers
Lifesciences
Biochemistry
Drug Development
Translational Medicine
Assay Development
Signal Transduction
Inflammation
Biologics
Validation
Clinical Research
Biopharmaceuticals
Protein Chemistry
Monoclonal Antibodies
IND
Formulation
Proteomics
Autoimmune Diseases
Genomics
Technology Transfer
Drug Delivery
Cancer Research
Infectious Diseases
Protein Purification
High Throughput Screening
DNA
Research
Public Speaking
Microsoft Excel
Science
Birgit Schultes Summary
Birgit Schultes, based in Arlington, MA, US, is currently a Chief Scientific Officer at Intellia Therapeutics, Inc.. Birgit Schultes brings experience from previous roles at Intellia Therapeutics, Inc., Unum Therapeutics and Momenta Pharmaceuticals. Birgit Schultes holds a 2009 - 2011 Advanced Management Development @ Boston University. With a robust skill set that includes Immunology, Oncology, Antibodies, Clinical Development, In Vitro and more. Birgit Schultes has 2 emails and 1 mobile phone numbers on RocketReach.
Looking for a different Birgit Schultes?
Find contact details for 700 million professionals.